What Antheia does

Antheia, Inc. is a U.S.-based synthetic biology company founded in 2015 out of the Smolke Lab at Stanford University by Dr. Christina Smolke (CEO) and Dr. Kristy Hawkins (CSO). The company engineers Saccharomyces cerevisiae (baker's yeast) to reconstruct complex plant-derived biosynthetic pathways of 25-30+ heterologous enzymes, enabling fermentation-based production of pharmaceutical Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) that historically have been sourced through agricultural cultivation or are intractable via chemical synthesis. Antheia operates fermentation at 116,000L commercial scale, has a pipeline of 70+ KSM/API targets across seven therapeutic categories (Neurology, Respiratory, Anti-infective, Oncology, Gastrointestinal, Endocrinology, Hematology), and brought its first commercial product — biosynthetic thebaine, the key ingredient in the opioid overdose reversal drug Narcan — to market in 2024.

Antheia monetizes the platform through direct enterprise B2B sales of KSMs and APIs to global pharmaceutical manufacturers on a quote-based pricing model under Standard Terms and Conditions of Sale, complemented by non-dilutive U.S. government project funding (DPA Title III via BioMaP-Consortium, $21M total as of March 2026) and a strategic manufacturing partnership with TAPI (Teva API) that uses TAPI's 13-site European fermentation footprint to scale production globally. The company maintains a pilot biomanufacturing plant in Menlo Park, California, a new Singapore innovation site, and sells into end-markets framed by the FDA and WHO Essential Medicines Lists, where approximately 78% of API manufacturers sit outside the U.S. and up to 50 new drug shortages per year persist.

The commercial motion is enterprise field sales supported by regulatory and policy engagement (DPA Title III, ASPR), conference participation (SynBioBeta, DCAT, Fierce JPM Week, SK pharmteco symposium), and thought-leadership content. AI/ML and advanced analytics are applied over fermentation datasets and off-gas mass spectrometry across 61 bioreactors to optimize bioprocess performance, but the differentiated output is the physical KSM/API product rather than a stand-alone software offering. Antheia is privately held, has raised more than $175M in cumulative capital over the past year (Series C plus non-dilutive government awards), and is led by founders Christina Smolke (CEO) and Kristy Hawkins (CSO) alongside a recently expanded executive bench (CFO Eric d'Esparbes, COO Zack McGahey, Chief People Officer Heidi Pucel, VP BD Chris Savile, VP Drug Innovation Adam Takos).

Name

Antheia

Legal name

Antheia, Inc.

Website

https://antheia.bio

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Antheia is a synthetic biology company that engineers yeast to produce biosynthetic Key Starting Materials and Active Pharmaceutical Ingredients, serving global pharmaceutical manufacturers and the U.S. government with essential medicines.

Ownership category

akta.pro rank

Product category

Pharmaceutical Ingredients (Biosynthetic KSMs and APIs)

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD)

akta.pro secondary industries

Biological Formulation, Fermentation & Scale-Up Manufacturing (AFABAEAM), Fermentation Nutrients & Media (Yeast Extracts, Peptones, Nitrogen Sources, Minerals) (AFAJAJAH)

Keywords

• Biosynthetic pharmaceutical ingredients
• Active pharmaceutical ingredients
• Key starting materials
• Synthetic biology manufacturing
• Yeast fermentation platform

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Sale of biosynthetic pharmaceutical ingredients (KSMs and APIs): B2B sale of pharmaceutical ingredients to drug manufacturers under per-Quotation pricing and Antheia's Standard Terms and Conditions of Sale (quote-based pricing, payment per Quotation, cancellation/reschedule fees tiered by notice window). Primary commercial revenue stream; first commercial delivery of thebaine (Narcan ingredient) executed.
2. U.S. government non-dilutive project funding: Non-dilutive funding from the U.S. Department of Health and Human Services via the BioMaP-Consortium under the Defense Production Act Title III Program to onshore pharmaceutical supply chains ($21M total project investment as of March 2026).
3. Strategic CDMO/manufacturing partnerships (capacity-as-a-service): Partnership with TAPI (Teva API) leverages TAPI's fermentation and API manufacturing footprint in Europe to scale and commercialize biosynthetic APIs/KSMs, effectively monetizing Antheia's platform through partner-operated production at global scale.
4. Government and foundation grants (historical): Historically received NSF grants (2016, 2018), NIH grants (2017, 2018), and Phase II SBIR grant (2018), supplementing equity and debt financing during R&D phase.

Pricing tiers

Go-to-market motion4 records

Distribution channels3 records

Marketing channels7 records

Core offering

Antheia manufactures biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines by engineering Saccharomyces cerevisiae yeast to reconstruct complex plant-derived biosynthetic pathways (25-30 enzymes) and producing them via industrial-scale fermentation at 116,000L. The company's first commercial product is thebaine (the key ingredient used to produce Narcan opioid overdose reversal drug, pain management medications, and alcohol use disorder treatments), with a pipeline of 70+ KSM/API candidates across neurology, respiratory, anti-infective, oncology, gastrointestinal, endocrinology, and hematology.

Product overview

Antheia offers a platform-plus-modules architecture built around its proprietary Advanced Biosynthesis Platform. The platform is a yeast-based, whole-cell engineering biomanufacturing system organized in four integrated phases (Build, Screen & Develop, Optimize, Scale) that uses reconstructed biosynthetic pathways of 25-30+ enzymes to ferment sugars into complex pharmaceutical ingredients — including Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) that previously could only be sourced through agricultural cultivation. Built on top of this platform, Antheia's product portfolio centers on commercial and pipeline KSM/API products: Thebaine (commercial stage, used in opioid overdose reversal drug Narcan, pain management, and alcohol use disorder treatments), Oripavine (related opioid KSM/API), Scopolamine (tropane alkaloid), and a deeper pipeline of internally designated products — ANT 104, ANT 105, ANT 106, ANT 108, ANT 206, ANT 302, ANT 401, ANT 402, and ANT 403 — collectively forming a pipeline of 70+ KSMs and APIs spanning Neurology, Respiratory, Anti-infective, Oncology, Gastrointestinal, Endocrinology, and Hematology therapeutic categories on the U.S. FDA Essential Medicines List. Antheia also operates a pilot biomanufacturing facility in Menlo Park, California (at 116,000L scale) and is establishing U.S. manufacturing operations and a Singapore site for drug innovation.

Differentiator

Problem solved

Functional benefit

Products and services

• Advanced Biosynthesis Platform Antheia's proprietary whole-cell engineering platform that reconstructs complex plant-derived biosynthetic pathways of 25-30+ heterologous enzymes in Saccharomyces cerevisiae yeast, then ferments them into KSMs and APIs at industrial scale (116,000L). Organized in four integrated phases — Build (genomic search and bioinformatics-driven yeast engineering), Screen & Develop (high-throughput strain characterization and downstream process development), Optimize (data-driven analytics, modeling, and AI/ML over fermentation datasets), and Scale (tech transfer to commercial manufacturing including the TAPI CDMO partnership).
• Thebaine Antheia's first commercial biosynthetic product. Thebaine is a benzylisoquinoline alkaloid KSM/API used as the key ingredient for producing Narcan (the opioid overdose reversal drug), pain management medications, and alcohol use disorder treatments. Currently at commercial stage on Antheia's pipeline.
• Oripavine Oripavine is an opiate alkaloid KSM/API produced via Antheia's yeast-based biosynthesis platform and listed in the pipeline alongside Thebaine as a related opioid pharmaceutical ingredient.
• Scopolamine Scopolamine is a tropane alkaloid KSM/API produced via Antheia's yeast-based biosynthesis platform, with therapeutic applications in neurology and gastrointestinal indications. The 2020 Nature publication on biosynthesis of medicinal tropane alkaloids in yeast from the Smolke Lab underpins this product.
• ANT-series pipeline KSM/API products Consolidated pipeline of additional biosynthetic KSM/API candidates designated ANT 104, ANT 105, ANT 106, ANT 108, ANT 206, ANT 302, ANT 401, ANT 402, and ANT 403. Part of Antheia's 70+ KSM/API portfolio spanning Neurology, Respiratory, Anti-infective, Oncology, Gastrointestinal, Endocrinology, and Hematology categories on the U.S. FDA Essential Medicines List.

Quantifiable outcome

• Reduced production timelines from approximately two years to two weeks for certain biosynthetic compounds.
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core and flagship / core.

• U.S. Administration for Strategic Preparedness and Response (ASPR)coreStrategic or Co-development Partner · 5 March 2026ASPR announced March 5, 2026 that it will invest in Antheia for domestic production of thebaine, an active pharmaceutical ingredient used in pain management medications, alcohol use disorder treatments, and opioid overdose reversal drugs. The investment reflects HHS/ASPR efforts to reduce reliance on foreign sources for essential medications and APIs.
• BioMaP-Consortium (Biopharmaceutical Manufacturing Preparedness Consortium), funded by U.S. HHS Defense Production Act Title III Programflagship / coreStrategic or Co-development Partner · 4 March 2026Expanded project agreement under which Antheia received an additional $9 million from the U.S. Department of Health and Human Services via BioMaP-Consortium and the DPA Title III Program, bringing total project investment to $21 million. Supports domestic commercial-scale production of two critical pharmaceutical ingredients using Antheia's advanced biosynthesis platform as part of broader onshoring of U.S. pharmaceutical supply chains.
• TAPI (Technology and API Services, a Teva API business)flagship / coreStrategic or Co-development Partner · 20 November 2025TAPI and Antheia announced a strategic partnership to scale production of biosynthetic APIs and KSMs using TAPI's fermentation expertise and manufacturing footprint in Europe (13 sites, 4,100 employees, 350+ products, 100+ countries). The collaboration supports Antheia's pipeline of pharmaceutical ingredients including thebaine, expands U.S. production capabilities, and aims to end drug shortages globally. Announced November 2025; ongoing tech transfer and scale-up work led by Antheia's Head of Fermentation Process Development & Scale-Up, Andrew Saarni.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Codexis: Codexis engineers enzymes and biocatalytic processes for pharmaceutical manufacturing, including APIs and intermediates. It is a direct peer to Antheia given its enzyme-engineering platform for pharmaceutical ingredient production, with comparable B2B pharma ingredient sales motion and overlap in leadership (Chris Savile, Antheia's new VP BD, previously served as Associate Director at Codexis).
• Amyris: Amyris pioneered yeast-based synthetic biology for ingredient production (personal care, flavors, fragrances). It is a direct peer to Antheia given its foundational yeast engineering platform and fermentation-based biomanufacturing model, with notable team overlap (multiple Antheia leaders previously worked at Amyris).
• Willow Biosciences: Willow Biosciences develops biosynthetic ingredients for pharmaceutical, consumer, and food applications using engineered yeast. It is a direct peer to Antheia given its biosynthetic API/KSM focus and Chris Savile's previous role as President and CEO of Willow.
• Ginkgo Bioworks: Ginkgo Bioworks operates a synthetic biology platform for cell engineering and organism design across multiple industries. It is a direct peer to Antheia given its yeast metabolic engineering capabilities, and Adam Takos (Antheia's new VP of Drug Innovation) previously led a $30M portfolio of drug discovery and yeast engineering programs at Ginkgo.
• Zymergen: Zymergen combined automation, machine learning, and synthetic biology for industrial biomanufacturing before being acquired by Ginkgo Bioworks. It is a comparable peer to Antheia given its fermentation-scale biomanufacturing focus, with notable team overlap (Antheia's COO Zack McGahey and Head of Quality Jesse Ahrendt previously led manufacturing and quality at Zymergen).
• LanzaTech: LanzaTech operates a synthetic biology platform using engineered microbes to convert waste gases into fuels, materials, and chemicals at commercial scale. It is a direct peer to Antheia given its industrial-scale fermentation-based biomanufacturing model and comparable platform architecture, though focused on different end markets.

Broad incumbents

• TAPI (Teva API): TAPI is the active pharmaceutical ingredient division of Teva, a global leader in API manufacturing with a large fermentation and small-molecule manufacturing footprint. It is a broad incumbent peer to Antheia given overlapping API manufacturing capabilities and its role as Antheia's strategic partner and global commercialization channel.
• Lonza: Lonza is a global contract development and manufacturing organization (CDMO) with large-scale fermentation and API manufacturing capabilities serving pharmaceutical customers. It is a broad incumbent peer given its scale, regulatory relationships, and pharma customer base that could compete with or partner around Antheia's biosynthetic platform.

Emerging players

• Conagen: Conagen is a synthetic biology company developing fermentation-based ingredients for food, beverage, flavor, and pharmaceutical applications. It is an emerging player peer given its overlapping fermentation platform for high-value ingredients, though it is smaller and less pharma-focused than Antheia.
• Geltor: Geltor is a synthetic biology company producing animal-free proteins and ingredients via fermentation. It is an emerging player peer given its fermentation-scale biomanufacturing focus and team overlap (Antheia's Andrew Saarni previously served as Director of Fermentation at Geltor), though Geltor focuses on protein ingredients rather than small-molecule APIs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/antheiabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles25 records

Subsidiaries1 record

Funding overview

Funding rounds12 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antheia